Recent paradigm-altering studies of sodium-glucose cotransporter-2 (SGLT2) inhibition have gone on to extend the relationship between change in ventricular remodelling and heart failure outcomes to also include patients with HFpEF. Here, SLC5A2 is linked to heart failure.